Overview

VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Status:
Recruiting

Trial end date:
2022-12-30

Target enrollment:

Participant gender:

Summary

In this study, we compared first-line VIC regimen with chemotherapy plus bevacizumab in Chinese patients with initially unresectable BRAF V600E-mutated mCRC. The principal goal was to evaluate the safety of VIC regimen, and to investigate the tumor response, the radical resectability, and the patient survival.

Phase:

Phase 3

Details

Lead Sponsor:

Fudan University

Treatments:

Bevacizumab